After hours: 5:34PM EDT
|Bid||115.70 x 900|
|Ask||115.76 x 1100|
|Day's Range||115.17 - 116.74|
|52 Week Range||96.99 - 134.55|
|Beta (3Y Monthly)||1.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 25, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||0.96 (0.78%)|
|1y Target Est||135.19|
First quarter corporate report cards generally have been good, with 75% or so of S&P; 500 companies beating earnings estimates, observes John Buckingham, value investing expert and editor of The Prudent Speculator.
The Fed made a material reversal at year-end and lower interest rates have fueled gains for both stocks and bonds. Unprecedented technological innovation is driving impressive productivity gains which has helped to keep inflation in check. Where socialism grows so does inflation and stagnation.
Zimmer Biomet Holdings Inc NYSE:ZBHView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for ZBH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZBH. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.67 billion over the last one-month into ETFs that hold ZBH are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The musculoskeletal healthcare company continues to try to turn things around, with limited success in the first quarter.
On a per-share basis, the Warsaw, Indiana-based company said it had net income of $1.20. Earnings, adjusted for one-time gains and costs, came to $1.87 per share. The results surpassed Wall Street expectations. ...
- Net sales of $1.976 billion for the first quarter represent a decrease of 2.1% from the prior year period, an increase of 0.7% on a constant currency basis - Diluted earnings per share for the first ...
With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.
SAN DIEGO, CA / ACCESSWIRE / April 24, 2019 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Zimmer Biomet Holdings Inc (NYSE: ZBH). Investors ...
WARSAW, Ind. , April 23, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, will participate in the Bank of America Merrill Lynch Healthcare ...
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet Holdings Inc (NYSE:ZBH) investors should be aware of a decrease in hedge fund sentiment in recent months. Zimmer Biomet Holdings Inc (ZBH) was in 36 hedge funds' portfolios at the end of the fourth quarter of 2018. There were 40 hedge funds in our database with ZBH positions at the end of the previous […]
With the FDA nod, Zimmer Biomet (ZBH) attains the status of being the first company to boast the 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform globally.
The platform features 3D intraoperative planning software in addition to a navigation suite of technologies designed to improve implant as well as instrument placement accuracy and predictability. "ROSA ONE Spine functions as a dual robotics and navigation technology solution for minimally invasive and complex thoracolumbar spine procedures," said Aure Bruneau, Zimmer Biomet's Group President, Spine, CMF and Thoracic and Surgery Assisting Technology.
WARSAW, Ind. , March 22, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter sales and earnings conference call will be broadcast over the Internet on ...
Zimmer Biomet (ZBH) has been working to strengthen foothold in emerging markets. However, the company has been facing continued pricing pressure.
WARSAW, Ind., March 12, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced it will be showcasing its latest commercial offerings and previewing its next generation of technological innovations at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, March 13-15 in Las Vegas, Nevada. "In addition to our ongoing commitment to advancing our traditional implant offering, Zimmer Biomet is transforming the patient journey through an ecosystem of differentiated solutions to provide more personalized care for the patient," said Bryan C. Hanson, President and CEO of Zimmer Biomet.
Jeff Krumpelman, chief investment strategist and head of equities at Mariner Wealth Advisors, and Kenny Polcari, managing principal at Butcher Joseph Asset Management, join CNBC's "The Exchange" to discuss mid-day markets and the stocks they're watching.